search
Back to results

Screening of Tobacco-induced Cancers by Low-dose CT-scanner and Identification of Circulating Tumor Cells (DETeCTOR)

Primary Purpose

Tobacco, Cancer, Screening

Status
Active
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
medical imaging
Identification of Circulating Tumor Cells
Psychological Questionnaires
Sponsored by
Fondation Hôpital Saint-Joseph
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional screening trial for Tobacco focused on measuring Circulating Tumor Cells, Lung

Eligibility Criteria

55 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Subject with at least a cumulative smoking 30 pack-years,
  • Active or weaned smoking since less than 15 years,
  • Who consults or is hospitalized in a medical services or vascular surgery 'Paris Saint Joseph Hospital Group' (GHPSJ) or 'the European Hospital Georges Pompidou' (HEGP) for occlusive arterial disease or aneurysm the abdominal aorta,
  • Accepting the repeat CT scans and blood tests, as provided for by the protocol and additional investigations which might be necessitated by the detection of abnormality (s) to previous reviews,
  • Accepting, in case of continuing active smoking, engage in smoking cessation process.

Exclusion Criteria:

  • Bronchial history of cancer,
  • Diagnosis and / or previous treatment of another cancer within 5 years prior to study entry, with the exception of skin tumors and non melanomatous carcinoma in situ,
  • Anterior resection pulmonary parenchyma, severe respiratory failure against-indicating any invasive procedure on the lung,
  • Signs of presence and / or symptoms that may be due to a pre-existing cancer (eg, unexplained weight loss of more than 10% of initial body weight over the last 12 months, hemoptysis, ...)
  • ECOG activity index ≥ 2,
  • Acute respiratory infection that led to antibiotic therapy within 12 weeks prior to study entry,
  • Renal impairment does not authorize, where appropriate, a contrast agent injection,
  • Comorbidity (s) may increase the risk of death during the course of the trial.

Sites / Locations

  • Groupe Hospitalier Paris Saint Joseph

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Screening program

Arm Description

Who consults or is hospitalized in a medical services or vascular surgery 'Paris Saint Joseph Hospital Group' (GHPSJ) or 'the European Hospital Georges Pompidou' (HEGP) for occlusive arterial disease or aneurysm the abdominal aorta. This population should accept to have a medical imaging Low-dose CT-scanner and an Identification of Circulating Tumor Cells on their blood. 30 first patients will be proposing to particpate to the psychologic sub-study by answering to a Psychological Questionnaires

Outcomes

Primary Outcome Measures

Assessment of change of the number of patients diagnosed by LDCT
number of patients diagnosed by LDCT (Low Dose CT-scanner)
Assessment change of the number of patients diagnosed with CTC identification
Number of patients diagnosed with CTC (Circulating Tumor Cells) identification

Secondary Outcome Measures

Assessment of the psychologic impact of screening a cancer
A psychologist-researcher attended with patient at the first consultation by the physician. The actual psychological study will be proposed as voluntary patients to participate (30 patients). It will consist of extensive interviews, lasting approximately 60 to 90 minutes, led by psychologist-researcher in principle without exceeding 3 interviews for each patient. These interviews will aim to assess the nature of the psychological impact that screening has had on you and your resources to cope

Full Information

First Posted
July 21, 2016
Last Updated
March 6, 2023
Sponsor
Fondation Hôpital Saint-Joseph
search

1. Study Identification

Unique Protocol Identification Number
NCT02849041
Brief Title
Screening of Tobacco-induced Cancers by Low-dose CT-scanner and Identification of Circulating Tumor Cells
Acronym
DETeCTOR
Official Title
Screening of Tobacco-induced Cancers by Low-dose CT-scanner and Identification of Circulating Tumor Cells
Study Type
Interventional

2. Study Status

Record Verification Date
March 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
January 23, 2017 (Actual)
Primary Completion Date
July 20, 2020 (Actual)
Study Completion Date
December 23, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Fondation Hôpital Saint-Joseph

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Tobacco smoke is the most common source of exposure to carcinogens in humans. Indeed, the smoke contains about 1010 particles per ml and 4800 chemical compounds, at least 66 are carcinogenic. Tobacco smoke is the leading preventable cause of cancer in humans since it is responsible for lung cancer, upper aerodigestive tract (mouth, pharynx, larynx, esophagus), nasal cavity and sinuses, stomach, pancreas, liver, bladder, kidney, uterine cervix, and some myeloid leukemias. This study aims to evaluate the combined effect of the scanner and the search for circulating tumor cells (CTC) on screening for tobacco-related cancers, accompanying smokers to cessation and addressing the psychological impact this approach.
Detailed Description
Study Objectives: The study takes two lines of research: 1 - Imaging and Research circulating tumor cells: The main objective is to evaluate the diagnostic value of the couple scanner low intensity and speed search of circulating tumor cells (CTC-LDCT) for screening in a population at high risk of lung cancer. The secondary objectives are: / comparing the added diagnostic value of dual-CTC LDCT screening that screening with LDCT used alone as it was used in the NLST study for lung cancer screening; / to assess the interest assess the diagnostic value of research of circulating tumor cells to identify extrapulmonary cancers associated with smoking; 3 / evaluate the psychological effects of screening (see psychological study). 2 - Psychological Study The main objective is to study the emotional and psychosocial consequences of LDCT screening in the specific context of circulating tumor cells. This is to identify 1 / specific mechanisms of fear, anxiety and mental distress, 2 / adaptation strategies that could be beneficial for other patients, 3 / specific stressors caused by the device screening and / or medical information given to patients. The secondary objective is to adjust and improve the communication skills of health professionals in order to develop an appropriate framework to support the emotional and psychological aspects involved in the screening process when ( will be) used daily in clinical practice. Study Design - Imaging and Research circulating tumor cells This is a prospective cohort study, multicenter (hospitals attached to the University Paris Descartes), open, non-randomized, single arm. Each subject enrolled in the study will undergo three screening procedures. Patients with cancer prevalent in the first exam will be offered treatment after the balance sheet. Only subjects who do not have cancer at the first examination will return to the actual screening study in search of incident cases. The same sequence of evaluation will be repeated once a year for 2 years. - Psychological Study To achieve the objectives, a qualitative study based on grounded theory ( "grounded theory") will be built. Grounded theory is a research methodology that studies the psychosocial processes to make them modeled theoretically. Since this method involves small samples of subjects, promotes flexibility of data collection and detailed analysis of the cases studied.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Tobacco, Cancer, Screening, Psychology, Lung
Keywords
Circulating Tumor Cells, Lung

7. Study Design

Primary Purpose
Screening
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
176 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Screening program
Arm Type
Experimental
Arm Description
Who consults or is hospitalized in a medical services or vascular surgery 'Paris Saint Joseph Hospital Group' (GHPSJ) or 'the European Hospital Georges Pompidou' (HEGP) for occlusive arterial disease or aneurysm the abdominal aorta. This population should accept to have a medical imaging Low-dose CT-scanner and an Identification of Circulating Tumor Cells on their blood. 30 first patients will be proposing to particpate to the psychologic sub-study by answering to a Psychological Questionnaires
Intervention Type
Device
Intervention Name(s)
medical imaging
Intervention Description
Low-dose CT-scanner
Intervention Type
Biological
Intervention Name(s)
Identification of Circulating Tumor Cells
Intervention Description
Research of circulating tumor cells in blood
Intervention Type
Procedure
Intervention Name(s)
Psychological Questionnaires
Intervention Description
The procedure of screening test could be stressful. "False positive" results can cause anxiety and lead to additional costs, as well as increased exposure to radiation and invasive medical examination. Although this is based on some objective results, there is a high probability of adverse psychological effects in case of false positives; so there is cause for concern in the short term anxiety associated with positive results and the use of additional tests during the intervals between screening phases. There is no data related to psychological distress potentially caused by the discovery of circulating tumor cells.
Primary Outcome Measure Information:
Title
Assessment of change of the number of patients diagnosed by LDCT
Description
number of patients diagnosed by LDCT (Low Dose CT-scanner)
Time Frame
Day 1, Month 6, Month 12
Title
Assessment change of the number of patients diagnosed with CTC identification
Description
Number of patients diagnosed with CTC (Circulating Tumor Cells) identification
Time Frame
Day 1, Month 6, Month 12
Secondary Outcome Measure Information:
Title
Assessment of the psychologic impact of screening a cancer
Description
A psychologist-researcher attended with patient at the first consultation by the physician. The actual psychological study will be proposed as voluntary patients to participate (30 patients). It will consist of extensive interviews, lasting approximately 60 to 90 minutes, led by psychologist-researcher in principle without exceeding 3 interviews for each patient. These interviews will aim to assess the nature of the psychological impact that screening has had on you and your resources to cope
Time Frame
Day 1,

10. Eligibility

Sex
All
Minimum Age & Unit of Time
55 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Subject with at least a cumulative smoking 30 pack-years, Active or weaned smoking since less than 15 years, Who consults or is hospitalized in a medical services or vascular surgery 'Paris Saint Joseph Hospital Group' (GHPSJ) or 'the European Hospital Georges Pompidou' (HEGP) for occlusive arterial disease or aneurysm the abdominal aorta, Accepting the repeat CT scans and blood tests, as provided for by the protocol and additional investigations which might be necessitated by the detection of abnormality (s) to previous reviews, Accepting, in case of continuing active smoking, engage in smoking cessation process. Exclusion Criteria: Bronchial history of cancer, Diagnosis and / or previous treatment of another cancer within 5 years prior to study entry, with the exception of skin tumors and non melanomatous carcinoma in situ, Anterior resection pulmonary parenchyma, severe respiratory failure against-indicating any invasive procedure on the lung, Signs of presence and / or symptoms that may be due to a pre-existing cancer (eg, unexplained weight loss of more than 10% of initial body weight over the last 12 months, hemoptysis, ...) ECOG activity index ≥ 2, Acute respiratory infection that led to antibiotic therapy within 12 weeks prior to study entry, Renal impairment does not authorize, where appropriate, a contrast agent injection, Comorbidity (s) may increase the risk of death during the course of the trial.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
TREDANIEL Jean, PhD, MD
Organizational Affiliation
Fondation Hôpital Saint-Joseph
Official's Role
Principal Investigator
Facility Information:
Facility Name
Groupe Hospitalier Paris Saint Joseph
City
Paris
State/Province
Ile-de-France
ZIP/Postal Code
75014
Country
France

12. IPD Sharing Statement

Plan to Share IPD
Undecided
Citations:
PubMed Identifier
31519196
Citation
Yannoutsos A, Fontaine M, Galloula A, Damotte D, Chatellier G, Paterlini-Brechot P, Meyer G, Pastre J, Duchatelle V, Marini V, Schwering KL, Lazareth I, Ghaffari P, Stansal A, Sanson H, Labrousse C, Beaussier H, Nasr NB, Zins M, Salmeron S, Messas E, Lajonchere JP, Emmerich J, Priollet P, Tredaniel J. Peripheral arterial disease and systematic detection of circulating tumor cells: rationale and design of the DETECTOR prospective cohort study. BMC Cardiovasc Disord. 2019 Sep 13;19(1):212. doi: 10.1186/s12872-019-1193-1.
Results Reference
derived

Learn more about this trial

Screening of Tobacco-induced Cancers by Low-dose CT-scanner and Identification of Circulating Tumor Cells

We'll reach out to this number within 24 hrs